Electromedical Technologies, Inc. (OTCQB: EMED) Seen As Poised To Emerge As A Leader In The Bioelectronics Industry For The Treatment Of Chronic And Acute Pain With Its FDA Cleared WellnessPro Plus Device, According To New Research Report Bullish On Future WellnessPlus POD And Its Remote Monitoring Portal

Posted November 24, 2020

In NASDAQ: AXSM, NYSE: BMY, NYSE: BSX, NYSE: GSK, NYSE: JNJ, NYSE: LLY, NYSE: MDT, NYSE: NVRO, NYSE: NVS, NYSE: TBA, OTCQB: EMED

Electromedical Technologies, Inc. (OTCQB: EMED) is seen as poised to emerge as a leader In the bioelectronics industry for the treatment of chronic and acute pain with its FDA cleared WellnessPro+ device, according to new research from Goldman Small Cap Research. The report is bullish on the future of WellnessPlus POD and its remote portal enabling physicians and technicians to monitor in real time remote view of therapy. The report projects 80,000 units sold by EMED in 2022.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

Electromedical Technologies, Inc. (OTCQB: EMED) Seen As Poised To Emerge As A Leader In The Bioelectronics Industry For The Treatment Of Chronic And Acute Pain With Its FDA Cleared WellnessPro Plus Device, according To New Research Report Bullish On Future WellnessPlus POD And Its Remote Monitoring Portal.

Bioelectronics blocks nerve signals naturally, far preferred to prescription pharmaceuticals that can have the harmful side effect of opioid addiction. Anticipating the on-boarding of hundreds of new medical practitioners and distributors, EMED is building up inventory of the devices as it transitions into 2021. Electromedical Technologies, Inc. (OTCQB: EMED) Seen As Poised To Emerge As A Leader In The Bioelectronics Industry For The Treatment Of Chronic And Acute Pain With Its FDA Cleared WellnessPro Plus Device, According To New Research Report Bullish On Future WellnessPlus POD And Its Remote Monitoring Portal.

The company has a purchase down payment/subscription payment revenue model which provides recurring revenue for sales of its devices. The upbeat forecast by Goldman SmallCap Research is largely based on prior sales of the FDA cleared Wellness Pro Plus device and forecast of the success of WellnessPlus POD. Analyst Rob Goldman was especially impressed with its telemedicine-like portal feature that permits physicians or technicians to monitor in real time how the wearable POD therapy is delivering relief from acute and chronic pain.

An Alternative To Possible Opioid Addicting Pharmaceuticals

Electromedical Technologies, Inc. (OTCQB: EMED has successfully marketed its non-invasive FDA-cleared WellnessPro Plus™ as an alternative treatment to opioid pain killer pharmaceuticals which can be addictive.

Inventory Build Up Is A Strategic Strategy Of Electromedical Technologies, Inc. (OTCQB: EMED)

For 2021, Matthew Wolfson, CEO, believes that patients who have experienced chronic pain relief from the bioelectronics and electro-modulation delivered by the Wellness Pro Plus devices warrants the inventory build-up. In anticipation of a rush for the product in 2021, the company has invested $4.2 Million as it builds 1,200+ unit inventory in preparation for attracting hundreds more medical practitioners and distributors in 2021.. Electromedical Technologies, Inc. (OTCQB: EMED) Seen As Poised To Emerge As A Leader In The Bioelectronics Industry For The Treatment Of Chronic And Acute Pain With Its FDA Cleared WellnessPro Plus Device, According To New Research Report Bullish On Future WellnessPlus POD And Its Remote Monitoring Portal.

Goldman Small Cap Research Last Week Set A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED)

Goldman Small Cap Research this week set a $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED), in an Opportunity Research report. The investment analysis projects that the medical device company will reach a volume of $17 Million in FY2022 and projects EMED will sell some 80,000 devices in 2022. It is encouraged by sales prospects for the WellnessPlus Pod. : Electromedical Technologies, Inc. (OTCQB: EMED) Seen As Poised To Emerge As A Leader In The Bioelectronics Industry For The Treatment Of Chronic And Acute Pain With Its FDA Cleared WellnessPro Plus Device, According To New Research Report Bullish On Future WellnessPlus POD And Its Remote Monitoring Portal.

The WellnessPlus Pod Seen Coming In Late 2021, After FDA Clearance

Electromedical Technologies, Inc. (OTCQB: EMED) can expect the WellnessPro Pod to be ready by late 2021 after anticipated FDA clearance by late 2021. The WellnessPlus POD is a smaller, professional, less costly device that features a special portal for telemedicine-like real time monitoring by physicians. The WellnessPro POD links doctors/technicians and patients with that feature and is less costly, smaller, portable and offers a remote POD portal. It also provides a unique financial sales structure for the Company, combining a down payment purchase with a recurring monthly subscription services fee.

Source: Stock Market Press

Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:

Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

Bina Murarka

Bina Murarka is a India-based technology reporter for Stock Market Press. A freelance writer who covered tech for various mainstream and financial websites, she writes about everything from small-cap telecommunications companies to the digital economy's impact on financial markets. She graduated from Calcutta University.